(Q33403930)

English

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

dedifferentiated liposarcoma

1 reference

based on heuristic

inferred from title

4

object named as

Axel Le Cesne

0 references

Isabelle Ray-Coquard

1

object named as

Isabelle Ray-Coquard

0 references

2

object named as

Jean-Yves Blay

0 references

object named as

Nicolas Penel

5

0 references

author name string

Antoine Italiano

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jianguo Zhi

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Florian Heil

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ruediger Rueger

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bradford Graves

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Meichun Ding

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David Geho

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Steven A Middleton

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lyubomir T Vassilev

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gwen L Nichols

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Binh Nguyen Bui

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

17 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1133-1140

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The p53 pathway: positive and negative feedback loops

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

MDM2 inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Well-differentiated and dedifferentiated liposarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The MDM2 gene amplification database

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential sensitivity of liposarcoma subtypes to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

mdm2 expression is induced by wild type p53 activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

TP53 mutations in human cancer: database reassessment and prospects for the next decade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free survival ratio as end point for phase II trials in advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970474-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70474-6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33403930&oldid=1536378254"